Conjugate Vaccine Market

The Global Conjugate Vaccine Market was worth of USD 27.00 Billion in 2026 and it is expected to reach USD 51.29 Billion by the end of 2033 with a CAGR of 9.6% during the Forecast Period.

Prevention of infectious disease, rising vaccination due to the various initiatives by government for immunization programs and technological advancement are anticipating the growth of global conjugate vaccine market. Global Conjugate Vaccine Market Size, Trends, Competitive, Historical & Forecast Analysis to 2026-2033.

Scope of Conjugate Vaccine Market Report:

A type of subunit that combines weak antigen with the strong antigen as a carrier to have a strong response from the immune system for weak antigen. Vaccine evokes the immune response to an antigen which in turn reacts & produces T cell and antibodies.  The most common weak antigen is the polysaccharide which is attached to the strong protein antigen and further protein/protein and peptide/protein conjugate has also developed. Along with this the Hib conjugate vaccine is commonly used. The first idea of conjugate vaccine published in 1927 which was done on rabbits when immune respond to the Streptococcus pneumoniae type 3 polysaccharide antigens & it was increased by combining the polysaccharide antigen. The first conjugate vaccine on human was developed in 1987 which was Haemophilus influenza type b which protects against meningitis.

COVID-19 pandemic has shown the negative impact on the manufacturing of the global conjugate vaccine market. COVID-19 has also disrupted the immunization plans world-wide. Pandemic has reduced the production of the conjugate vaccine due to lack of workforce and disrupted supply chain. The pandemic has also caused the sealing of the border to avoid the spread of corona virus which indirectly hampered the transportation from one region to another. According to world-o-meter, the confirmed cases of corona virus are 262 266,768,000505,478 in which almost 5,278,749 died by 7th Dec’2021.

Conjugate Vaccine Market Segmentation:

Global conjugate vaccine market is segmented on the basis of indication, type, end user, and region and country level. Based on the indication the global conjugate vaccine market is classified into meningococcal, influenza, pneumococcal and others. Based on the type the global conjugate vaccine market is classified into monovalent, multivalent, and others. Based on the end user the global conjugate vaccine market is classified into adults, pediatrics.

By indication:

• Meningococcal
• Influenza
• Pneumococcal
• Others

By type:

• Monovalent
• Multivalent
• Others

By end-user:

• Adults
• Pediatrics

The regions covered in this global conjugate vaccine market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East ,GCC, (UAE, Saudi Arabia, Kuwait) Africa, etc.

Conjugate Vaccine Manufacturers

Some major key players for the global conjugate vaccine market report cover prominent players like.

• Sanofi Pasteur Limited
• Pfizer Inc.
• GlaxoSmithKline
• Taj Pharmaceutical limited
• Fablife, Bavarian Nordic
• CSL Limited
• Bharat Biotech
• Novartis AG
• Merck & Co., Inc.,
• And others

News: “PREVNAR 20” launched by Pfizer’s pneumococcal 20- valent conjugate vaccine for adults.

June 8th, 2021: Pfizer’s launched its first 20- valent conjugate vaccine PREVNAR 20 which is approved by FDA, and it helps to protect against 20 serotypes which is responsible for the pneumococcal disease and pneumonia.  This vaccine is used for people of age 18 years or older. PREVNAR 20 is a capsule polysaccharide conjugates for the 13 serotypes including PREVNAR 13 as well in it. The 3 phases are evaluating the safety, immunogenicity of vaccine, in which more than 60,000 adults above 18 years and older participated in the trails.

Rising demand for vaccination due to the various initiatives by government for immunization programs, prevention of infectious disease, and technological advancement are anticipating the growth of global conjugate vaccine market.

The factor that boosts the global conjugate vaccine market is the various initiatives taken by government as per the growing demand amongst people. Universal Immunization Program is one of the largest public health programs targeting close to 29 million pregnant women and 26.7 million newborns annually. Also the expansion of Pneumococcal Conjugate Vaccine under this program has been launched in the year 2021. According to the WHO, almost 95% of the pneumococcal conjugate vaccine is given to infants. Along with this around 152 countries have fully or partially introduced routine PCV immunization of infants.

Another factor that drives the market in this region is the rising geriatric population with weaken immune system and increased awareness for the prevention of infectious diseases. Rising population will require more number of conjugate vaccines in order to prevent themselves from various infections. According to the sciencedirect, the pneumococcal conjugate vaccines have prevented almost 175 million cases and 624,000 deaths globally. As per the rules and regulation of the government for new innovation of vaccine and there manufacturing cost will act as a restraining factor of the global conjugate vaccine market. On the other hand the development and innovation and increasing investment will bring new opportunities in the global conjugate vaccine market.

North America continues its domination in the Global Conjugate Vaccine Market.

The favorable conditions for the vaccine development, followed by the increased awareness for vaccination among people and government initiatives for immunization has fueled the market in the North America region. High education and high standard of living has increased the awareness among people for vaccination. According to WHO, almost 1.6 million death occurred in U.S. due to pneumococcus in which around 800,000 are children below 5 years. Since 2000 a seven valent pneumococcal conjugate vaccine has been licensed in U.S. and has shown tremendous reduction in transmission from spreading of pneumococcal disease. 

Another factor that drives the market in this region is initiatives taken by government for immunization programs or plans to reduce the burden on the countries for serious diseases. The expanded immunization program was launched by WHO in 1974, in which almost the death rate in the infants falls from 9.6 million to 7.6 million under age 5 in the year 2010. This national immunization programs has been supported by the GAVI, UNICEF, and PAHO. According to the immunization program an affordable conjugate vaccine against Neisseria meningitides (meningococcus) serogroup A was developed with international collaboration. According to CDC, in 2019, there were 371 cases of meningococcus diseases in U.S.

Although, Asia Pacific is witnessing the highest growth over the forecast period due to the large population followed by government initiatives, rising investment by the key players are showing tremendous growth in this region.  China has the largest population in Asia Pacific followed by India which is also the reason to increase the conjugate vaccine in this region including the prevalence of communicable disease.  The Navi Mumbai municipal corporation (India) introduced typhoid conjugate vaccine in their immunization program for the children of age 9 months to 14 years in the year 2018. According to the academic group, the vaccination covered almost 71% of the children from this age. Along with this the India ranks second in the population in Asia Pacific and 8.3 million cases are confirmed on typhoid disease and 72,400 deaths per year. 

On Special Requirement Conjugate Vaccine  Market Report is also available for below region:

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America
• Middle East and Africa

Saudi Arabia

• UAE
• Egypt
• South Africa
• Rest Of MEA 

Report Analysis	Details
Historical data	2020 - 2025
Forecast Period	2026 - 2033
Market Size in 2026:	USD 27.00 Billion
Base year considered	2025
Forecast Period CAGR %:	9.6%
Market Size Expected in 2033:	USD 51.29 Billion
Tables, Charts & Figures:	175
Pages	200
Conjugate Vaccine Manufacturers	Sanofi Pasteur Limited, Pfizer Inc., GlaxoSmithKline, Taj Pharmaceutical limited, Fab life, Bavarian Nordic, CSL Limited, Bharat Biotech, Novartis AG, Merck & Co., Inc., And others
Segments Covered	By indication, By Type, By end-user
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

 

Key Benefits for Global Conjugate Vaccines Report

• Global Conjugate Vaccines report covers in-depth historical and forecast analysis.
• Global Conjugate Vaccines research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Conjugate Vaccine Manufacturers, Competitive Analysis, Regional and Country Level.
• Global Conjugate Vaccines report helps to identify opportunities in the marketplace.
• Global Conjugate Vaccines report covers extensive analysis of emerging trends and competitive landscape.

Other Top Trending Reports:

• Medical Aesthetics Market Size, Share & Trends Analysis Report 2021-2027
• Outdoor Furniture Market Size, Share, Manufacturers & Trends Analysis Report 2021-2027